接受放射治疗的肝细胞癌患者的免疫反应和结果评估
接受放射治疗的肝细胞癌患者免疫反应和结果的前瞻性评估
Radiation therapy is a highly effective modality for managing localized solid tumors and has become a fundamental component of treating unresectable hepatocellular carcinoma. Our previous preclinical investigation revealed that radiotherapy can initiate immunogenic cell death and facilitate the cross-presentation of tumor antigens by antigen-presenting cells, thereby augmenting systemic anti-tumor T cell responses in murine tumor models. However, this immune response subsequent to irradiation has not been comprehensively evaluated in clinical trials involving hepatocellular carcinoma patients. Given that radiotherapy represents a standard therapeutic approach for unresectable hepatocellular carcinoma, our ongoing phase II non-randomized trial aims to prospectively assess immunological responses and dose-volumetric parameters, while identifying predictors of clinical outcomes in patients undergoing definitive radiotherapy for hepatocellular carcinoma.
研究概览
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Rodney Cheng-En Hsieh, MD, PhD
- 电话号码:7000 +886-3-3281200
- 邮箱:chsieh@cgmh.org.tw
学习地点
-
-
Taiwan
-
Taoyuan City、Taiwan、台湾、333
- 招聘中
- Chang Gung Memorial Hospital at Linkou
-
接触:
- Rodney Cheng-En Hsieh, MD, PhD
- 电话号码:7000 +88633281200
- 邮箱:rodney445@gmail.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Patients undergoing routine radiotherapy using photons or protons for HCC
描述
Inclusion Criteria:
-
Participants must have diagnosis of HCC. Participants may have multiple lesions. Diagnosis should be confirmed by at least 1 criteria listed below:
- Histologically or cytologically proven diagnosis of HCC.
- Typical arterial enhancement and delayed washout on multiphasic CT or MRI.
-
Age ≥18 years at the time of signing informed consent document.
-
ECOG performance status 0-2.
-
Child-Pugh score 5-9 liver function within 28 days of study registration.
-
Documented virology status of hepatitis B virus (HBV), as confirmed by screening HBV serology test.
-
Documented virology status of hepatitis C virus (HCV), as confirmed by screening HCV serology test.
-
Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Presence of distant metastases that cannot be encompassed by radiotherapy
- Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception
- Inability to treat all sites of disease by radiotherapy
- Known HIV infection.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Radiotherapy
Definitive photon or proton radiotherapy |
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression free survival (PFS)
大体时间:12 months
|
PFS is defined as the time from signing the informed consent to the first occurrence of disease progression or death from any cause (whichever occurs first) according to RECIST1.1. |
12 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Local control (LC)
大体时间:12 months
|
LC is defined as the time from signing the informed consent to the first occurrence of disease progression in the irradiated field according to RECIST1.1. |
12 months
|
|
Time to progression (TTP)
大体时间:12 months
|
TTP is defined as the time from signing the informed consent to the first occurrence of disease progression according to RECIST1.1. |
12 months
|
|
Overall Response Rate (ORR)
大体时间:12 months
|
ORR is defined as a complete or partial response according to RECIST1.1. |
12 months
|
|
Overall survival (OS)
大体时间:12 months
|
OS is defined as the time from signing the informed consent to death from any cause. |
12 months
|
|
Incidence and severity of adverse events
大体时间:12 months
|
Adverse events will be graded using CTCAE v5 |
12 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 202400364B0
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Sharing individual participant data (IPD) with other researchers requires IRB review and approval. Presently, we do not have a plan to provide IPD to other researchers
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.